Camber Pharmaceuticals Recalls Antifungal Drug Due to Contamination Risk

Camber Pharmaceuticals has recalled one lot of Atovaquone oral suspension, USP 750mg/5mL because of the possible contamination with Bacillus cereus — bacteria found in soil, plants and food.

The antifungal drug is approved for treatment of adults and children 13 years and older with pneumocystis pneumonia — a potentially deadly fungal infection of the lungs — who cannot tolerate other medicines.

Immunocompromised patients are at highest risk from the potential bacterial contamination, which can cause life-threatening infections such as endocarditis and necrotizing soft tissue infections.

The affected lot was distributed nationwide, but the company has not received any reports of adverse events related to the issue.

Related Topics